ENDRA Life Sciences has a quick ratio of 3.36. It generally indicates good short-term financial strength.
The historical rank and industry rank for ENDRA Life Sciences's Quick Ratio or its related term are showing as below:
NDRA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.11 Med: 3.23 Max: 7.72
Current: 3.36
During the past 10 years, ENDRA Life Sciences's highest Quick Ratio was 7.72. The lowest was 0.11. And the median was 3.23.
NDRA's Quick Ratio is ranked better than 71.19% of 236
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.91
vs NDRA: 3.36
ENDRA Life Sciences Quick Ratio Historical Data
The historical data trend for ENDRA Life Sciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ENDRA Life Sciences's Quick Ratio
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's Quick Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Quick Ratio falls into.
ENDRA Life Sciences Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
ENDRA Life Sciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NAS:NDRA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
ENDRA Life Sciences Quick Ratio Related Terms
Thank you for viewing the detailed overview of ENDRA Life Sciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your 